The pharmacokinetics and pharmacodynamics of medifoxamine after oral administration in healthy elderly volunteers.
The pharmacokinetics and psychomotor effects of medifoxamine, a 5 HT reuptake inhibitory antidepressant, were studied in healthy elderly volunteers after single and multiple dosing. The elimination half life (t1/2z) after single doses of 300 mg was 2.8 h--almost identical to that found in young volunteers. After seven days of dosing at 100 mg three times daily the mean corrected AUC after 300 mg significantly increased from 1.04 to 1.34 mg.h.l-1 and t1/2z increased to 4.0 h (NS). There were no significant changes in critical flicker fusion frequency, symbol digit substitution, continuous attention or choice reaction times.
Department of Health Care of the Elderly, King's College School of Medicine and Dentistry, London, UK.
N
N
Gainsborough
M L
ML
Nelson
V
V
Maskrey
C G
CG
Swift
S H
SH
Jackson
D000284:Administration, Oral; D000368:Aged; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D005021:Ethylamines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D011597:Psychomotor Performance / Q000187:drug effects*; D012016:Reference Values
D000928:Antidepressive Agents; D005021:Ethylamines; C034065:medifoxamine